A groundbreaking discovery from Cold Spring Harbor Laboratory (CSHL) promises to reshape the therapeutic landscape for estrogen receptor-positive (ER+) breast cancer, a disease subtype constituting approximately 75% of breast cancer cases globally. Despite the widespread use of hormone therapies like tamoxifen, resistance remains a formidable clinical challenge, often culminating in disease recurrence and metastasis. This new research shines a light on the pivotal role of the protein BPTF in modulating the aggressiveness and treatment responsiveness of ER+ tumors.
ER+ breast cancers owe their growth to signals mediated by estrogen receptors, which hormone therapies aim to block. However, the genetic and epigenetic plasticity of tumors can drive them to evolve mechanisms to bypass these blocks, resulting in relapse and metastatic spread with hormone therapy-resistant disease. Addressing these resistance pathways is crucial as it could dramatically enhance the durability of remission and patient survival. The study led by CSHL Associate Professor Camila dos Santos breaks novel ground by exploring the biological functions of BPTF, a transcription factor previously underestimated in breast cancer biology.
BPTF, or Bromodomain PHD Finger Transcription Factor, regulates chromatin remodeling and gene transcription, thereby influencing cell growth and differentiation. Previous studies had indicated that knocking out BPTF could slow tumor growth but did not prevent tumor formation itself, causing pharmaceutical interest to wane. However, dos Santos’s team revisited BPTF’s role with a nuanced approach. By crossbreeding established murine ER+ breast cancer models with BPTF knockout strains, the researchers uncovered remarkable retention of hormone receptor positivity throughout tumor progression—something unseen before in any mouse model.
What differentiates this model is that the tumors sustained their reliance on estrogen receptor signaling without drifting towards hormone independence, a typical pathway leading to therapy resistance in conventional models. This biological consistency allowed the researchers to test the efficacy of tamoxifen under BPTF-deficient conditions, revealing that tumors exhibited a significant and sustained susceptibility to the drug. This suggests that BPTF activity is instrumental in steering tumors toward resistance phenotypes by potentially altering chromatin states or transcriptional programs associated with hormone receptor regulation.
Further experimental exploration employed advanced organoid cultures, human breast cancer cell lines, and genetically engineered mouse models that recapitulate hormone therapy resistance. Across these sophisticated systems, the abrogation of BPTF synergized with tamoxifen treatment to restore hormone sensitivity, inducing tumor growth arrest. This convergence underscores a potentially targetable axis between epigenetic modulation and hormone therapy response, offering a tangible route to overcoming drug resistance in patients.
The implications of these findings are far-reaching for the clinical management of ER+ breast cancer. Current hormone therapies, although effective initially, provide temporary reprieve for many patients due to the evolution of resistant clones. Targeting BPTF could ‘reprogram’ resistant tumor cells back into a hormone-dependent state, essentially repositioning cancer cells along a vulnerability that current therapies can exploit. Such an approach would not only delay recurrence but could fundamentally change how breast cancers are treated post-resistance development.
This discovery also exemplifies the importance of detailed, mechanistic cancer biology research over simplistic binary analyses of tumor presence or absence. Graduate student Dhivyaa Anandan highlighted that deciphering tumor heterogeneity, growth patterns, and metastatic behaviors was critical to uncovering these insights—affirming that nuanced investigation often reveals therapeutic avenues that remain invisible in more reductive models.
Mechanistically, BPTF’s impact may lie in its chromatin remodeling functions that alter transcriptional landscapes governing estrogen receptor expression and downstream signaling networks. By influencing histone modifications or nucleosome positioning, BPTF may facilitate tumor cell plasticity and adaptive resistance. Disabling BPTF may disrupt these epigenetic programs, restricting tumor cells from rewiring their signaling pathways to evade hormone therapies.
From a translational perspective, pharmacological inhibitors of BPTF or strategies to diminish its expression could be developed as adjuvant treatments alongside tamoxifen and other selective estrogen receptor modulators. This combinatorial approach would potentially enhance patient outcomes by maintaining hormone therapy sensitivity and preventing metastatic dissemination. Given the prevalence of ER+ breast cancer and the substantial subset of patients experiencing recurrence, these findings herald a promising new therapeutic horizon.
Beyond breast cancer, this research spotlights the broad therapeutic potential of targeting transcription factors and chromatin remodelers—oft-overlooked players in oncogenesis that critically modulate cancer cell identity and drug responsiveness. As the research community pioneers novel epigenetic drugs, insights like those from the dos Santos lab provide conceptual and experimental foundations for next-generation cancer therapies.
In conclusion, the discovery that BPTF suppression retains ER+ identity and reinstates hormone therapy sensitivity is a beacon of hope in the fight against breast cancer metastasis and resistance. By integrating sophisticated genetic models, in vitro cultures, and human tumor studies, this research bridges fundamental biology and clinical application, setting the stage for innovative interventions that could transform patient trajectories. The scientific community eagerly anticipates further developments, including clinical translation, toward more durable cures for ER+ breast cancer.
Subject of Research: Estrogen receptor-positive (ER+) breast cancer, hormone therapy resistance, and the role of BPTF transcription factor.
Article Title: Not specified in the source.
News Publication Date: Not specified in the source.
Web References:
- Nature Communications article DOI: 10.1038/s41467-025-64255-8
- Camila dos Santos lab at CSHL: https://www.cshl.edu/research/faculty-staff/camila-dos-santos/
References:
- Original research article in Nature Communications linking BPTF knockout to restored hormone therapy sensitivity in ER+ breast cancer models.
Image Credits: dos Santos lab / Cold Spring Harbor Laboratory
Keywords: Transcription factor binding, Transcription factors, Estrogen, Breast neoplasms, Breast cancer, Metastasis
